Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Sandrock

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Annals of Clinical and Translational Neurology|October 27, 2021
Measuring treatment response to advance precision medicine for multiple sclerosisPeter A Calabresi, Ludwig Kappos, Gavin Giovannoni, et al.
Annals of Neurology|August 26, 2010
Anti-JC virus antibodies: implications for PML risk stratificationLeonid Gorelik, Michaela Lerner, Sarah Bixler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2024
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumabTianle Chen, John O'Gorman, Carmen Castrillo-Viguera, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Nature|September 2, 2016
The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Annals of Clinical and Translational Neurology|October 27, 2021
Measuring treatment response to advance precision medicine for multiple sclerosisPeter A Calabresi, Ludwig Kappos, Gavin Giovannoni, et al.
Annals of Neurology|August 26, 2010
Anti-JC virus antibodies: implications for PML risk stratificationLeonid Gorelik, Michaela Lerner, Sarah Bixler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2024
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumabTianle Chen, John O'Gorman, Carmen Castrillo-Viguera, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Nature|September 2, 2016
The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Pageof 2